<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792632</url>
  </required_header>
  <id_info>
    <org_study_id>Aidence01</org_study_id>
    <nct_id>NCT04792632</nct_id>
  </id_info>
  <brief_title>Clinical Performance Evaluation of Veye Lung Nodules</brief_title>
  <acronym>CPEVLN</acronym>
  <official_title>Clinical Performance Evaluation of Veye Lung Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aidence</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aidence</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Veye Lung Nodules (Aidence B.V., Amsterdam, the Netherlands) is a medical software device&#xD;
      that is intended to assist radiologists with pulmonary nodule management on CT chest scans.&#xD;
&#xD;
      This clinical trial aims to assess the clinical performance of Veye Lung nodules via a&#xD;
      standalone performance evaluation and a reader study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection accuracy</measure>
    <time_frame>2 months</time_frame>
    <description>Demonstrate that the accuracy for detecting actionable pulmonary nodules by radiologists using the device (AIDED) is superior to that of radiologists not using the device (UNAIDED)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Segmentation accuracy</measure>
    <time_frame>1 month</time_frame>
    <description>Demonstrate that the accuracy for segmenting actionable pulmonary nodules by the device is non-inferior to expert radiologists</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Growth assessment accuracy</measure>
    <time_frame>1 month</time_frame>
    <description>Demonstrate that the accuracy for determining volume change of actionable pulmonary nodules by the device is non-inferior to expert radiologists</description>
  </other_outcome>
  <other_outcome>
    <measure>Composition classification accuracy</measure>
    <time_frame>2 months</time_frame>
    <description>Demonstrate that the accuracy for classifying the composition of actionable pulmonary nodules by radiologists using the device (AIDED) is superior to that of radiologists not using the device (UNAIDED)</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Lung; Node</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <description>Intervention is the use of Veye Lung Nodules during the reading of the CT scans</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Veye Lung nodules</intervention_name>
    <description>Veye Lung Nodules</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        US adult population that received a CT chest scan either as part of a lung cancer screening&#xD;
        program or during routine practice&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Subjects that underwent a CT chest scan for either lung cancer screening or routine&#xD;
        practice&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with &gt;10 pulmonary nodules;&#xD;
&#xD;
          -  Subjects with pulmonary mass(es) = largest axial diameter &gt;30mm;&#xD;
&#xD;
          -  Subjects with interstitial lung disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Joris Wakkie, Ms</last_name>
    <phone>+31624561754</phone>
    <email>joris@aidence.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Intrinsic Imaging</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>01740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <phone>978-634-2200</phone>
      <email>Contact@IntrinsicImaging.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

